Peptide Comparison
Semax vs Dihexa
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Semax has stronger documented evidence (Russia-Approved + Anecdotal) than Dihexa (Preclinical + Anecdotal) while both occupy the nootropic class. When clinical-evidence tier is the deciding factor, Semax is the safer pick. Dihexa may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Semax | Dihexa | |
|---|---|---|
| Class | ACTH fragment analog; nootropic | Angiotensin IV analog; HGF potentiator |
| Drug class | Cognitive | Cognitive |
| Mechanism | Upregulates BDNF and NGF; modulates dopamine and serotonin systems; neuroprotective | Enhances HGF/c-Met signaling; promotes synaptogenesis and dendritic spine formation |
| Route | Intranasal / SC | Oral / Transdermal |
| Half-life | ~5-15 min (intranasal peak) | ~10 hrs |
| Dosage (research) | 200 mcg intranasal daily (0.1% solution, 2-3 drops per nostril, nootropic starting dose, max 600 mcg/day per Russian clinical literature for stroke and cognitive support) | 8-45 mg oral daily (anecdotal) |
| Evidence tier | Russia-Approved + Anecdotal | Preclinical + Anecdotal |
| Research depth | 150 indexed | 17 indexed |
| Availability | Research / Intl Rx | Research Chemical |
| Reported risks | Mild irritability; insomnia; nasal irritation with intranasal use | Very limited human data; theoretical tumor risk via HGF pathway |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Semax or Dihexa?
Semax has stronger documented evidence (Russia-Approved + Anecdotal) than Dihexa (Preclinical + Anecdotal) while both occupy the nootropic class. When clinical-evidence tier is the deciding factor, Semax is the safer pick. Dihexa may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Semax and Dihexa?
Semax is classed as ACTH fragment analog; nootropic; Dihexa is classed as Angiotensin IV analog; HGF potentiator. Reported mechanism: Semax, Upregulates BDNF and NGF; modulates dopamine and serotonin systems; neuroprotective; Dihexa, Enhances HGF/c-Met signaling; promotes synaptogenesis and dendritic spine formation. Reported half-life: Semax, ~5-15 min (intranasal peak); Dihexa, ~10 hrs. Routes in published studies: Semax, Intranasal / SC; Dihexa, Oral / Transdermal.
Which has stronger evidence, Semax or Dihexa?
Semax has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Semax is graded Russia-Approved + Anecdotal, with 5 cited sources on its reference page and 150 indexed studies. Dihexa is graded Preclinical + Anecdotal, with 2 cited sources on its reference page and 17 indexed studies.
Which is more accessible, Semax or Dihexa?
Neither Semax nor Dihexa is an FDA-approved drug. Catalog status: Semax, Research / Intl Rx; Dihexa, Research Chemical. Semax's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn. Dihexa's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are Semax and Dihexa ever combined?
Semax and Dihexa appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…